Results 91 to 100 of about 47,525 (299)

Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms [PDF]

, 2006
BACKGROUND: Extrapyramidal syndromes (EPS) are clinically relevant side effects of metoclopramide which are often not anticipated. PATIENTS AND METHODS: Two patients who received metoclopramide developed an acute dystonic reaction ...
Padt, A. van der, Schaik, R.H.N. (Ron) van, Sonneveld, P. (Pieter)   +2 more
core   +1 more source

Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer [PDF]

, 2007
OBJECTIVE: Xenobiotic-metabolizing enzymes are widely polymorphic and confer interindividual variation in the ability to detoxify carcinogens or to activate pro-carcinogens.
Carrilho, F, Carvalheiro, M, Coutinho, E, Gomes, L, Lemos, MC, Regateiro, FJ, Rodrigues, F   +6 more
core   +1 more source

GenoStaR: An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics enables the personalization of drug therapy by linking genetic variations to differences in drug metabolism, efficacy, and risk of adverse reactions. Genetic polymorphisms within cytochrome P450 (CYP) genes significantly affect enzyme activity, influencing drug plasma levels, responses, and safety.
Alex J. Coulter, Megana Thamilselvan, James L. Kennedy, Clement C. Zai, Arun K. Tiwari   +4 more
wiley   +1 more source

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

Pharmacogenomics and Personalized Medicine, 2014
Junji Saruwatari,1 Hiroo Nakashima,1 Shoko Tsuchimine,2 Miki Nishimura,1 Naoki Ogusu,1 Norio Yasui-Furukori21Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; 2Department of ...
Saruwatari J, Nakashima H, Tsuchimine S, Nishimura M, Ogusu N, Yasui-Furukori N   +5 more
doaj  

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing [PDF]

, 2019
PURPOSE: A number of institutions have clinically implemented CYP2D6 genotyping to guide drug prescribing. We compared implementation strategies of early adopters of CYP2D6 testing, barriers faced by both early adopters and institutions in the process
Beitelshees, Amber L., Bell, Gillian C., Bishop, Jeffrey R., Blake, Kathryn, Cavallari, Larisa H., Crona, Daniel J., Dressler, Lynn, Duong, Benjamin Q., Empey, Philip E., Gregg, Ryan A., Hicks, J. Kevin, Hines, Lindsay J., Johnson, Julie A., Lee, James C., Limdi, Nita A., Obeng, Aniwaa Owusu, Peterson, Josh F., Pratt, Victoria M., Prows, Cynthia A., Ramsey, Laura B., Scott, Stuart A., Shelton, Richard C., Skaar, Todd C., Smith, D. Max, Tuteja, Sony, Van Driest, Sara L., Weitzel, Kristin Wiisanen   +26 more
core   +1 more source

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

Clinical Pharmacology &Therapeutics, EarlyView.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel, Filippa Schreeck, Simon Jaeger, Severin Schricker, Elke Schaeffeler, Svitlana Igel, Daniela Steinberger, Manuel Pagitz, Jörg Latus, Markus Ketteler, Kerstin Bühl, Marc‐H. Dahlke, Hans‐Georg Kopp, Matthias Schwab   +13 more
wiley   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [PDF]

, 2015
Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety.
Bishop, Jeffrey R., Caudle, Kelly E., Chiulli, Dana L., Gaedigk, Andrea, Graham, Rebecca L., Hicks, J. Kevin, Ji, Yuan, Klein, Teri E., Leckband, Susan G., Leeder, J. Steven, LLerena, Adrián, Müller, Daniel J, Sangkuhl, Katrin, Scott, Stuart A., Skaar, Todd C., Stingl, Julia C.   +15 more
core   +1 more source

Dietary‐Driven Gene Expansion

Clinical Pharmacology &Therapeutics, EarlyView.
Gene duplication has been shown to drive molecular evolution, with dietary pressures expanding detoxification genes across species. In humans, CYP2D6 gene duplications enhance alkaloid and drug metabolism, reflecting ancient dietary adaptations. Similarly, tobacco‐feeding aphids amplify CYP6CY3 for nicotine and insecticide resistance, and as recently ...
Magnus Ingelman‐Sundberg
wiley   +1 more source

Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions

Pharmacogenomics and Personalized Medicine, 2021
Chiara Jeiziner,1 Céline K Stäuble,1,2 Markus L Lampert,1 Kurt E Hersberger,1 Henriette E Meyer zu Schwabedissen2 1Pharmaceutical Care Research Group, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland ...
Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer zu Schwabedissen HE   +4 more
doaj  

Fluoxetine: a case history of its discovery and preclinical development [PDF]

, 2014
Introduction: Depression is a multifactorial mood disorder with a high prevalence worldwide. Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS ...
Bel N, Bergstrom RF, Bravo L, Bremner JD, Burrows GD, Chouinard G, Datla KP, Esther Berrocoso, Juan Antonio Mico, Kreiss DS, Laura Perez-Caballero, Lemberger L, Li Q, Lidia Bravo, Maj J, Nibuya M, Owens MJ, Rutter JJ, Sonia Torres-Sanchez, Stevens JC, Wong DT   +20 more
core   +2 more sources